Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06800924
Active, not recruiting Observational

Posture and Spinal Mobility in Anorexia Nervosa

NCT06800924 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-06-06
Last updated
2026-03-30

Condition(s) studied

Anorexia Nervosa

Investigational drug(s) / intervention(s)

Postural and mobility analysis

Postural and mobility analysis: Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)

Study summary

The primary objective of the study is to compare the results of the postural and mobility analysis obtained with the use of the Idiag M360 instrument in adult women with anorexia nervosa and in a control group represented by age-matched normal-weight women.

Secondary objectives will be to correlate the results obtained from previous postural analyses with anthropometric parameters, the duration and onset of the disease, and the presence/date of onset of secondary amenorrhea.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Anorexia Nervosa: Inclusion Criteria: * Female sex * Age 18 years and older * Anorexia nervosa clinically diagnosed based on the DSM-5 criteria * Hospitalized in the Division of Eating and Nutrition Disorders (END), Istituto Auxologico Italiano, IRCCS, Piancavallo (VB), Italy Exclusion Criteria: * Absence of signed informed consent * Musculoskeletal or neurological conditions (leg length discrepancy, spinal deformities, and physical disabilities caused by surgery) * Treatment with anti-inflammatory drugs Normal Weight: Inclusion Criteria: * Female sex * Age 18 years and older * BMI: 18.5-24.9 kg/m2 * Recruited from the medical/nursing and research staff Exclusion Criteria: * Absence of signed informed consent * Musculoskeletal or neurological conditions (leg length discrepancy, spinal deformities, and physical disabilities caused by surgery) * Treatment with anti-inflammatory drugs

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istituto Auxologico Italiano IRCCS, Site Piancavallo Oggebbio Verbania

More Istituto Auxologico Italiano trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06800924 on ClinicalTrials.gov ↗ ← All trials in Italy